



The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee July 2022 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection¹
1	Burosumab	Crysvita	Endocrine system	Pending	Pending further information
2	Cabotegravir	Vocabria	Infections	Approved	
3	Daratumumab	Darzalex	Malignant disease and immunosuppression	Approved	
4	Enzalutamide	Xtandi	Malignant disease and immunosuppression	Approved	
5	Estradiol	Vagifem	Endocrine system	Approved	
6	Guselkumab	Tremfya	Musculoskeletal and joint disease	Approved	
7	Nintedanib	Ofev	Respiratory system	Pending	Pending further information
8	Ofatumumab	Kesimpta	Malignant disease and immunosuppression	Approved	
9	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Approved	
10	Rilpivirine	Rekambys	Infections	Approved	
11	Risdiplam	Evrysi	Musculoskeletal and joint disease	Pending	Pending further information
12	Selumetinib	Koselugo	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.